AstraZeneca Plc’s Lynparza improved survival in people with late-stage pancreatic cancer, one of the most difficult tumors to treat, in an advanced clinical trial.
The disease was less likely to worsen in patients who got the drug after receiving standard chemotherapy than in those who received a placebo, the company said Feb. 26 in a statement.
The outcome is the first positive result for a drug like Lynparza, a so-called PARP inhibitor, in pancreatic cancer, Astra oncology head Jose Baselga said in the statement, and the company will discuss the results with global health authorities. The trial’s success is another ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.